Your browser doesn't support javascript.
loading
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa, Kazuhiko; Garon, Edward B; Seto, Takashi; Nishio, Makoto; Ponce Aix, Santiago; Paz-Ares, Luis; Chiu, Chao-Hua; Park, Keunchil; Novello, Silvia; Nadal, Ernest; Imamura, Fumio; Yoh, Kiyotaka; Shih, Jin-Yuan; Au, Kwok Hung; Moro-Sibilot, Denis; Enatsu, Sotaro; Zimmermann, Annamaria; Frimodt-Moller, Bente; Visseren-Grul, Carla; Reck, Martin.
Afiliação
  • Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan. Electronic address: nakagawa@med.kindai.ac.jp.
  • Garon EB; David Geffen School of Medicine at University of California Los Angeles, Translational Research in Oncology US Network, Los Angeles, CA, USA.
  • Seto T; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ponce Aix S; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain.
  • Paz-Ares L; Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Clinical Research Unit, Universidad Complutense and Ciberonc, Madrid, Spain.
  • Chiu CH; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Park K; Samsung Medical Center, Division of Hematology and Oncology, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Novello S; Department of Oncology, University of Turin, Azienda ospedaliero-universitaria San Luigi, Orbassano, Italy.
  • Nadal E; Department of Medical Oncology, Catalan Institute of Oncology, and Clinical Research in Solid Tumors group, Oncobell, l'Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet, Barcelona, Spain.
  • Imamura F; Osaka International Cancer Institute, Osaka, Japan.
  • Yoh K; National Cancer Center Hospital East, Kashiwa, Japan.
  • Shih JY; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Au KH; Queen Elizabeth Hospital, Kowloon, Hong Kong.
  • Moro-Sibilot D; Grenoble University Hospital, Grenoble, France.
  • Enatsu S; Eli Lilly Japan KK Kobe, Kobe, Japan.
  • Zimmermann A; Eli Lilly and Company, Indianapolis, IN, USA.
  • Frimodt-Moller B; Eli Lilly and Company, Copenhagen, Denmark.
  • Visseren-Grul C; Lilly Oncology, Utrecht, Netherlands.
  • Reck M; LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Lancet Oncol ; 20(12): 1655-1669, 2019 12.
Article em En | MEDLINE | ID: mdl-31591063
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article